Trial Profile

A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valsartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide
Indications Hypertension; Obesity
Focus Therapeutic Use
Acronyms VITAE
Sponsors Novartis; Novartis Pharmaceuticals

01 Aug 2010 Results, detailing the comparative effects of valsartan/hydrochlorothiazide with those of hydrochlorothiazide + amlodipine on fasting and post-prandial glucose and insulin levels, have been published in the Journal of Hypertension.
28 Oct 2008 Actual patient number (412) added as reported by ClinicalTrials.gov.
28 Oct 2008 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com